美股詳情

本頁面由Tiger Fintech (Singapore) Pte. Ltd.提供服務

基因編輯

389.60

+3.420.89%

漲家數：5

跌家數：1

平家數：- -

市盈率：- -

高：395.96

開：386.50

低：378.08

收：386.19

資料載入中...

總覽新聞資訊

Editas Medicine, Inc.盤中異動早盤急速跳水5.73%報1.81美元

藍鳥生物盤中異動早盤大幅下跌6.00%報3.84美元

重磅！藍鳥生物被收購！

昔日千億市值獨角獸，被收購

生物科技馆

Beam Therapeutics Inc.盤中異動股價大跌5.07%

Crispr Therapeutics Ag盤中異動下午盤股價大跌5.02%報47.90美元

Editas Medicine, Inc.盤中異動早盤股價大漲12.62%報2.32美元

藍鳥生物股價重挫29.55% 市值跌1424.96萬美元

BUZZ-藍鳥生物因與凱雷、SK Capital 達成折價私有化交易而下跌

基因療法生產商藍鳥公司將在資金緊張的情況下通過折價交易實現私有化

藍鳥生物同意被凱雷和 SK Capital 收購

Crispr Therapeutics Ag盤中異動股價大漲5.15%報54.91美元

藍鳥生物盤中異動早盤股價大跌5.20%報6.75美元

Intellia Therapeutics, Inc.盤中異動急速拉昇5.03%

Editas Medicine, Inc.盤中異動快速拉昇5.17%

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/stock/BK4556/news?page=3"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"BK4556"},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK4556\",,,,,undefined,":{"symbol":"BK4556","market":"US","secType":"PLATE","nameCN":"基因編輯","latestPrice":389.60336,"timestamp":1741208399999,"preClose":386.18573,"halted":0,"volume":19681301,"delay":0,"changeRate":0.00885,"change":3.417633,"pbRate":1.873032,"amount":138049805.511814,"amplitude":0.046291,"prevYearClose":376.62552,"fiveDayClose":408.0821,"twentyDayClose":376.4462,"turnoverRate":0.03606,"marketCap":7238271108,"floatMarketCap":6793444364,"peRate":-3.692897},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK4556\",,,,,undefined,":{"symbol":"BK4556","high":395.95972,"amplitude":0.046291,"preClose":386.18573,"low":378.08292,"pbRate":"1.873032","latestPrice":389.60336,"volume":19681301,"delay":0,"open":386.49673,"prevYearClose":376.62552,"prevWeekClose":396.1103,"prevMonthClose":396.1103,"prevQuarterClose":376.6255,"fiveDayClose":408.0821,"twentyDayClose":376.4462,"sixtyDayClose":408.5231,"secType":"PLATE","market":"US","turnoverRate":0.03606,"peRate":-3.692897,"marketCap":7238271108,"floatMarketCap":6793444364,"timestamp":1741208399999,"nameCN":"基因編輯"},"@#url:\"https://hq.skytigris.cn/api/global/plate/up_down\",method:\"POST\",data:#delay:false,bkCodes:@\"BK4556\",,,,undefined,":{"bkCode":"BK4556","up":5,"down":1,"flat":0},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BK4556\",pageSize:16,pageCount:3,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2513496720","title":"Editas Medicine, Inc.盤中異動 早盤急速跳水5.73%報1.81美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2513496720","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2513496720?lang=zh_tw&edition=fundamental","pubTime":"2025-02-24 22:52","pubTimestamp":1740408766,"startTime":"0","endTime":"0","summary":"北京时间2025年02月24日22时52分，Editas Medicine, Inc.股票出现异动，股价快速跳水5.73%。Editas Medicine, Inc.股票所在的生物技术行业中，整体涨幅为0.06%。其相关个股中，Pepgen Inc.、Estrella Immunopharma Inc C/Wts 29/09/2028、Telix Pharmaceutic涨幅较大，Pepgen Inc.、Aditxt, Inc.、Biodexa Pharmaceuticals Plc较为活跃，换手率分别为132.80%、54.81%、25.03%，振幅较大的相关个股有Pepgen Inc.、Telix Pharmaceutic、Aspire Biopharma Holdings Inc C/Wts 14/02/2030 ，振幅分别为137.23%、55.69%、41.14%。Editas Medicine, Inc.公司简介：Editas Medicine Inc 是一家临床阶段基因组编辑公司，致力于开发具有潜在变革性的基因组药物来治疗各种严重疾病。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250224225246962e9e16&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250224225246962e9e16&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4556","BK4139","EDIT"],"gpt_icon":0},{"id":"2513722444","title":"藍鳥生物盤中異動 早盤大幅下跌6.00%報3.84美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2513722444","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2513722444?lang=zh_tw&edition=fundamental","pubTime":"2025-02-24 22:33","pubTimestamp":1740407617,"startTime":"0","endTime":"0","summary":"北京时间2025年02月24日22时33分，蓝鸟生物股票出现波动，股价急速下跌6.00%。截至发稿，该股报3.84美元/股，成交量24.78万股，换手率2.54%，振幅2.72%。机构评级方面，在所有7家参与评级的机构中，14%的券商给予买入建议，86%的券商给予持有建议，无券商给予卖出建议。蓝鸟生物股票所在的生物技术行业中，整体跌幅为0.01%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202502242233379890f5f6&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202502242233379890f5f6&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4578","BK4139","BLUE","BK4556"],"gpt_icon":0},{"id":"2513279513","title":"重磅！藍鳥生物被收購！","url":"https://stock-news.laohu8.com/highlight/detail?id=2513279513","media":"谈思生物","labels":["corporation","merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2513279513?lang=zh_tw&edition=fundamental","pubTime":"2025-02-22 19:00","pubTimestamp":1740222016,"startTime":"0","endTime":"0","summary":"根据协议条款，蓝鸟生物的股东将获得每股3.00美元的现金，以及每股或有价值权。然而，该交易需满足以下条件：获得蓝鸟生物大部分已发行股份的投标、获得必要的监管批准以及其他常规成交条件。蓝鸟生物的董事会已一致批准该协议，并建议股东投标其股份。交易完成后，蓝鸟将转为私营公司，其普通股将不再在任何公开市场交易。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250222193457abd8979b&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250222193457abd8979b&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"corporation,merge","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4135","IE00BGHQF748.EUR","BK4139","IE00B64PRP62.GBP","IE00B3QW5Z07.USD","BK4556","BLUE","BK4578","CG"],"gpt_icon":1},{"id":"2513324053","title":"昔日千億市值獨角獸，被收購","url":"https://stock-news.laohu8.com/highlight/detail?id=2513324053","media":"生物科技馆","labels":["merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2513324053?lang=zh_tw&edition=fundamental","pubTime":"2025-02-22 10:17","pubTimestamp":1740190645,"startTime":"0","endTime":"0","summary":"明星Biotech蓝鸟生物，昔日千亿市值独角兽，最终还是选择了“卖身”。当地时间2月21日，蓝鸟生物宣布，将被全球投资公司凯雷和由SK Capital管理的基金收购。据外媒最新消息，根据协议条款，蓝鸟生物股东将获得每股3美元的现金，这意味着其股权价值为2916万美元；投资公司还提供了每股6.84美元的额外支付，这代表约6648万美元的付款，但条件是达到所约定的销售里程碑。最终总计，交易总额约1亿美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250222101943abd83c24&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250222101943abd83c24&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"merge","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4578","BK4556","BK4139","BLUE"],"gpt_icon":1},{"id":"2513899211","title":"Beam Therapeutics Inc.盤中異動 股價大跌5.07%","url":"https://stock-news.laohu8.com/highlight/detail?id=2513899211","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2513899211?lang=zh_tw&edition=fundamental","pubTime":"2025-02-22 03:07","pubTimestamp":1740164828,"startTime":"0","endTime":"0","summary":"北京时间2025年02月22日03时07分，Beam Therapeutics Inc.股票出现异动，股价快速下跌5.07%。截至发稿，该股报31.46美元/股，成交量84.827万股，换手率1.02%，振幅7.39%。Beam Therapeutics Inc.股票所在的生物技术行业中，整体涨幅为0.34%。Beam Therapeutics Inc.公司简介：Beam Therapeutics Inc 是一家从事基于其碱基编辑技术创造基因药物的生物技术公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250222030709abd7e75f&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250222030709abd7e75f&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BEAM","LENZ","BK4556","BK4535","BK4585","BK4588","BK4139","BK4505"],"gpt_icon":0},{"id":"2513219328","title":"Crispr Therapeutics Ag盤中異動 下午盤股價大跌5.02%報47.90美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2513219328","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2513219328?lang=zh_tw&edition=fundamental","pubTime":"2025-02-22 03:00","pubTimestamp":1740164429,"startTime":"0","endTime":"0","summary":"北京时间2025年02月22日03时00分，Crispr Therapeutics Ag股票出现异动，股价急速下挫5.02%。截至发稿，该股报47.90美元/股，成交量153.512万股，换手率1.79%，振幅7.02%。Crispr Therapeutics Ag股票所在的生物技术行业中，整体涨幅为0.43%。Crispr Therapeutics Ag公司简介：CRISPR Therapeutics AG是一家基因编辑公司，专注于开发基于Crispr/Cas9的疗法。Crispr/Cas9是成簇的规则间隔短回文重复序列/Crispr相关蛋白9的缩写，是精确改变基因组DNA特定序列的革命性技术。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250222030029988e16bc&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250222030029988e16bc&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","LENZ","LU1861559042.SGD","LU1861558580.USD","BK4588","BK4556","BK4585","CRSP"],"gpt_icon":0},{"id":"2513144296","title":"Editas Medicine, Inc.盤中異動 早盤股價大漲12.62%報2.32美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2513144296","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2513144296?lang=zh_tw&edition=fundamental","pubTime":"2025-02-21 22:31","pubTimestamp":1740148277,"startTime":"0","endTime":"0","summary":"北京时间2025年02月21日22时31分，Editas Medicine, Inc.股票出现异动，股价快速拉升12.62%。Editas Medicine, Inc.股票所在的生物技术行业中，整体涨幅为0.33%。其相关个股中，Osr Holdings, Inc.、Nkgen Biotech, Inc.、Acelyrin, Inc.涨幅较大，Nkgen Biotech, Inc.、Aditxt, Inc.、蓝鸟生物较为活跃，换手率分别为69.10%、60.32%、17.96%，振幅较大的相关个股有Osr Holdings, Inc.、Gain Therapeutics, Inc.、Windtree Therapeutics, Inc.，振幅分别为14.17%、10.21%、7.71%。Editas Medicine, Inc.公司简介：Editas Medicine Inc 是一家临床阶段基因组编辑公司，致力于开发具有潜在变革性的基因组药物来治疗各种严重疾病。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250221223117a24eb010&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250221223117a24eb010&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4556","BK4139","EDIT"],"gpt_icon":0},{"id":"2513296386","title":"藍鳥生物股價重挫29.55% 市值跌1424.96萬美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2513296386","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2513296386?lang=zh_tw&edition=fundamental","pubTime":"2025-02-21 22:31","pubTimestamp":1740148274,"startTime":"0","endTime":"0","summary":"北京时间2025年02月21日22时31分，蓝鸟生物股票出现异动，股价急速跳水29.55%。截至发稿，该股报4.96美元/股，成交量165.059万股，换手率16.98%，振幅1.25%。蓝鸟生物股票所在的生物技术行业中，整体涨幅为0.33%。其相关个股中，Osr Holdings, Inc.、Nkgen Biotech, Inc.、Acelyrin, Inc.涨幅较大，Nkgen Biotech, Inc.、Aditxt, Inc.、蓝鸟生物较为活跃，换手率分别为69.02%、60.21%、17.19%，振幅较大的相关个股有Osr Holdings, Inc.、Gain Therapeutics, Inc.、Windtree Therapeutics, Inc.，振幅分别为11.30%、10.21%、7.29%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250221223114abd7af49&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250221223114abd7af49&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","BK4578","BLUE","BK4556"],"gpt_icon":0},{"id":"2513926037","title":"BUZZ-藍鳥生物因與凱雷、SK Capital 達成折價私有化交易而下跌","url":"https://stock-news.laohu8.com/highlight/detail?id=2513926037","media":"路透中文","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2513926037?lang=zh_tw&edition=fundamental","pubTime":"2025-02-21 21:22","pubTimestamp":1740144142,"startTime":"0","endTime":"0","summary":"** BLUE 在 2024 年下跌了 69.8(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250221:nL3T3PC14W:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4556","CG","BLUE","BK4578","IE00B64PRP62.GBP","IE00B3QW5Z07.USD","BK4139","IE00BGHQF748.EUR","BK4135"],"gpt_icon":0},{"id":"2513262096","title":"基因療法生產商藍鳥公司將在資金緊張的情況下通過折價交易實現私有化","url":"https://stock-news.laohu8.com/highlight/detail?id=2513262096","media":"路透中文","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2513262096?lang=zh_tw&edition=fundamental","pubTime":"2025-02-21 20:58","pubTimestamp":1740142714,"startTime":"0","endTime":"0","summary":"更新版 3-基因疗法生产商蓝鸟公司将在资金紧张的情况下通过折价交易实现私有化在第 6 和第 7 段添加分析师评论Sneha  S K. 路透社2月21日 - 基因疗法生产商蓝鸟生物BLUE.O周五同意由凯雷集团CG.O和SK Capital Partners以折扣价私有化，在此之前，蓝鸟生物曾因基因疗法艰难的市场环境导致现金紧缩而长期挣扎。Skysona获批治疗一种罕见的神经系统疾病，Zynteglo获批治疗一种名为β-地中海贫血的血液疾病。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250221:nL3S3PC135:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4556","CG","IE00B64PRP62.GBP","IE00B3QW5Z07.USD","BK4135","BK4139","IE00BGHQF748.EUR","BK4578","BLUE"],"gpt_icon":0},{"id":"2513628602","title":"藍鳥生物同意被凱雷和 SK Capital 收購","url":"https://stock-news.laohu8.com/highlight/detail?id=2513628602","media":"路透中文","labels":["corporation","merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2513628602?lang=zh_tw&edition=fundamental","pubTime":"2025-02-21 20:36","pubTimestamp":1740141414,"startTime":"0","endTime":"0","summary":"蓝鸟生物同意被凯雷和 SK Capital 收购路透社2月21日 - 青鸟生物BLUE.O周五表示，该公司已与全球投资公司凯雷CG.O和SK Capital Partners管理的基金达成收购协议。 (为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250221:nL3S3PC12D:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,merge","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4556","BK4135","CG","BK4139","BLUE","IE00B3QW5Z07.USD","BK4578","IE00BGHQF748.EUR","IE00B64PRP62.GBP"],"gpt_icon":0},{"id":"2512486511","title":"Crispr Therapeutics Ag盤中異動 股價大漲5.15%報54.91美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2512486511","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2512486511?lang=zh_tw&edition=fundamental","pubTime":"2025-02-19 23:17","pubTimestamp":1739978246,"startTime":"0","endTime":"0","summary":"北京时间2025年02月19日23时17分，Crispr Therapeutics Ag股票出现波动，股价急速拉升5.15%。截至发稿，该股报54.91美元/股，成交量120.4万股，换手率1.40%，振幅4.96%。Crispr Therapeutics Ag股票所在的生物技术行业中，整体涨幅为0.50%。Crispr Therapeutics Ag公司简介：CRISPR Therapeutics AG是一家基因编辑公司，专注于开发基于Crispr/Cas9的疗法。Crispr/Cas9是成簇的规则间隔短回文重复序列/Crispr相关蛋白9的缩写，是精确改变基因组DNA特定序列的革命性技术。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202502192317269628d551&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202502192317269628d551&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LENZ","BK4556","BK4139","CRSP","BK4585","LU1861559042.SGD","BK4588","LU1861558580.USD"],"gpt_icon":0},{"id":"2512248655","title":"藍鳥生物盤中異動 早盤股價大跌5.20%報6.75美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2512248655","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2512248655?lang=zh_tw&edition=fundamental","pubTime":"2025-02-19 23:12","pubTimestamp":1739977972,"startTime":"0","endTime":"0","summary":"北京时间2025年02月19日23时12分，蓝鸟生物股票出现异动，股价急速下挫5.20%。截至发稿，该股报6.75美元/股，成交量3.3504万股，换手率0.34%，振幅3.47%。机构评级方面，在所有10家参与评级的机构中，20%的券商给予买入建议，60%的券商给予持有建议，20%的券商给予卖出建议。蓝鸟生物股票所在的生物技术行业中，整体涨幅为0.47%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250219231253a24c0468&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250219231253a24c0468&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","BK4578","BK4556","BLUE"],"gpt_icon":0},{"id":"2512833914","title":"Intellia Therapeutics, Inc.盤中異動 急速拉昇5.03%","url":"https://stock-news.laohu8.com/highlight/detail?id=2512833914","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2512833914?lang=zh_tw&edition=fundamental","pubTime":"2025-02-19 22:37","pubTimestamp":1739975820,"startTime":"0","endTime":"0","summary":"北京时间2025年02月19日22时37分，Intellia Therapeutics, Inc.股票出现异动，股价大幅上涨5.03%。Intellia Therapeutics, Inc.股票所在的生物技术行业中，整体跌幅为0.01%。Intellia Therapeutics, Inc.公司简介：Intellia Therapeutics 是一家基因编辑公司，致力于开发基于 Crispr/Cas9 的疗法。Intellia 致力于利用这项技术治疗基因定义的疾病。Intellia 已与多家公司建立了合作关系，以推进其产品线的发展，其中包括窄膜 Regeneron 和宽膜 Novartis。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202502192237009628ce54&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202502192237009628ce54&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","LENZ","NTLA","LU1861559042.SGD","LU1861558580.USD","BK4588","BK4556","BK4585","BK4535"],"gpt_icon":0},{"id":"2512483685","title":"Editas Medicine, Inc.盤中異動 快速拉昇5.17%","url":"https://stock-news.laohu8.com/highlight/detail?id=2512483685","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2512483685?lang=zh_tw&edition=fundamental","pubTime":"2025-02-19 22:35","pubTimestamp":1739975756,"startTime":"0","endTime":"0","summary":"北京时间2025年02月19日22时35分，Editas Medicine, Inc.股票出现异动，股价大幅拉升5.17%。Editas Medicine, Inc.股票所在的生物技术行业中，整体跌幅为0.02%。其相关个股中，Osr Holdings Inc C/Wts 02/09/2028 、Neurosense Therapeutics Ltd C/Wts 10/11/2026 、Aditxt, Inc.涨幅较大，Aditxt, Inc.、Alzamend Neuro, Inc.、Chemomab Therapeutics Ltd较为活跃，换手率分别为259.20%、205.80%、66.76%，振幅较大的相关个股有Osr Holdings Inc C/Wts 02/09/2028 、Aditxt, Inc.、Azitra Inc，振幅分别为207.68%、19.64%、16.40%。Editas Medicine, Inc.公司简介：Editas Medicine Inc 是一家临床阶段基因组编辑公司，致力于开发具有潜在变革性的基因组药物来治疗各种严重疾病。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250219223557988b3226&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250219223557988b3226&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["EDIT","BK4556","BK4139"],"gpt_icon":0}],"pageSize":16,"totalPage":3,"pageCount":3,"totalSize":47}]}}